News update on Samumed WNT pathway activator hair loss treatment.  Wnt pathway has been extensively studied in recent years and has been implicated in many degenerative diseases and conditions including androgenetic alopecia or pattern baldness in men and women. Samumed, one of the leading biotech companies in Wnt pathway modulation has officially started their phase 2/3 trial for SM04554 for the treatment of androgenetic alopecia. Click Samumed WNT Pathway Activator Hair Loss Treatment for the latest updates and anticipated commercial availability date.